News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
Experts
ScoPo’s powerplays: Antisense ‘looks like it wants to run harder’
Health & Biotech
Check Up: Eco-fibre play Nanollose leads ASX healthcare sector with 292% gain
Experts
ScoPo’s powerplays: Searching for gems as healthcare sector languishes
News
Closing Bell: Today’s biggest small cap movers on the ASX
Experts
ScoPo’s Powerplays: Despite recent losses, healthcare is a great sector to be in
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Antisense Therapeutics receives FDA orphan designation for muscular dystrophy treatment
Experts
ScoPo’s Powerplays: Healthcare companies raised $1bn year-to-date
Experts
ScoPo’s Health Powerplays: Biotechs hitting it out of the park
Health & Biotech
Antisense’s DMD drug could have ‘profound’ impact on boys
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Who’s trading insults today?
Health & Biotech
Antisense Therapeutics’ FDA ruling could be worth ‘hundreds of millions’
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Experts
ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs
Experts
